{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-007689","form_type":"8-K","ticker":"TMCI","cik":"0001630627","company_name":"TREACE MEDICAL CONCEPTS, INC.","filed_at":"2022-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.460962+00:00","generated_at":"2026-06-27T18:38:15.008548+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Treace Medical prelim Q4 rev $33.1-33.4M, FY rev $94.1-94.4M (+64-65% YoY)","bullets":["Preliminary Q4 2021 revenue $33.1M-$33.4M (up 37-39% YoY); FY 2021 revenue $94.1M-$94.4M (up 64-65% YoY).","Full-year revenue at high end of prior guidance range of $90M-$95M.","Sequential Q4 revenue growth of 53-54% vs Q3 2021.","CEO cites strength of direct sales channel, DTC, and surgeon training programs.","Company to provide 2022 financial guidance on Q4 earnings call."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-007689","json":"https://secwatch.observer/filing/0001193125-22-007689.json","markdown":"https://secwatch.observer/filing/0001193125-22-007689.md","text":"https://secwatch.observer/filing/0001193125-22-007689.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1630627/000119312522007689/0001193125-22-007689-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1630627/000119312522007689/d264837d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T18:38:15.008548+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}